Results 71 to 80 of about 4,014 (178)

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Stability indicating RP-HPLC method development and validation for the simultaneous determination of Sofosbuvir and Velpatasvir in tablet dosage forms [PDF]

, 2017
Stability indicating RP-HPLC method was developed for the simultaneous quantitation of Sofosbuvir and Velpatasvir in its pharmaceutical dosage form and validated.
Ganapaty, S., Bandla, Jahnavi, Jahnavi Bandla, S. Ganapaty   +3 more
core   +1 more source

Efficacy and Safety of 12‐Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi‐Center Prospective Study

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT To assess the sustained virologic response (SVR12) and safety profile of 12‐week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)‐infected patients across genotypes in Northwest China. This prospective cohort study (2023–2024) enrolled HCV patients from 12 clinical centers in Northwest China, adhering to the China Hepatitis ...
Lu Yan, Maimaitijiang Wubuliaishan, Xiaoni Kou, Maimaitiaili Tuerxun, Mingbo Yang, Fanpu Ji, Yingli He, Jiuping Wang, Longdong Zhu, Xiaohong Gao, Fuchun Jing, Xiangchun Ding, Hong Du, Ye Zhang, Hong Jiang   +14 more
wiley   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Sofosbuvir/velpatasvir: A promising combination

World Journal of Hepatology, 2016
Hepatitis C virus (HCV) affects 3% of the world population. It represents the main cause of chronic liver disease and is responsible for extra-hepatic complications, such as type 2 diabetes and cardiovascular diseases. HCV includes 7 genotypes differing in the nucleotide sequence variability, the geographic distribution, the rates of viral clearance ...
BONAVENTURA, ALDO, MONTECUCCO, FABRIZIO
openaire   +2 more sources

Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection

, 2018
Introduction: Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized.
Santosh Kumar, Mu, Ying, Sunitha Kodidela, Kodidela, Sunitha, Gong, Yuqing, Cory, Theodore J., Ying Mu, Theodore J. Cory, Yuqing Gong, Kumar, Santosh   +9 more
core   +1 more source

Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir [PDF]

Altres ajuts: acords transformatius de la UABSofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs).
Fernández, Inmaculada, Calleja, Jose Luis, Ruiz Cobo, Juan Carlos, Castellote, Jose, Buti, Maria, Rodríguez-Seguel, Elisa, Andrade Bellido, Raúl Jesús, Badia Aranda, E., Cuenca, Beatriz de, Gallego Moya, Adolfo, Morillas Cunill, Rosa Ma, Jimeno Maté, Carlota, Morillas, Rosa María, Andrade, Raul J., Rosales Zabal, Jose Miguel, Llerena, Susana, Delgado, Manuel, Lens, Sabela, Llaneras Artigues, Jordi, Bernal-Monterde, Vanesa, García-Samaniego, Javier, Mateos Muñoz, Beatriz, Álvarez-Rodríguez, Manuel, Diago, Moises, González Santiago, Jesús M., Ruiz-Cobo, Juan Carlos, Andrade, Raul J, Montoliu, Silvia, Badia Aranda, Ester, Rodríguez, Manuel, Llaneras, Jordi, Rodríguez Seguel, Elisa del Pilar, Forns, Xavier, Arencibia, Ana, Universitat Autònoma de Barcelona, Conde Amiel, Isabel, González-Santiago, Jesús M, Conde, Isabel, Hernandez-Guerra, Manuel, de Cuenca, Beatriz, Bernal-Monterde, V., Turnes, Juan, Maté, Carlota Jimeno, Mateos, Beatriz, Forns, X., Calleja Panero, José Luis, García-Samaniego Rey, Francisco Javier, Llaneras, J., Ruiz Cobo, J. C., Rodríguez García, Manuel   +49 more
core   +3 more sources

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection [PDF]

The Korean Journal of Internal Medicine, 2023
Hyun Phil Shin
doaj   +1 more source